Ki Chung to Humans
This is a "connection" page, showing publications Ki Chung has written about Humans.
Connection Strength
0.053
-
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology. 2011; 81(2):65-72.
Score: 0.015
-
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010 Jul 20; 28(21):3485-90.
Score: 0.013
-
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer. 2022 01; 163:19-26.
Score: 0.007
-
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021 10 01; 27(19):5236-5247.
Score: 0.007
-
A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers. Oncologist. 2021 09; 26(9):e1499-e1507.
Score: 0.007
-
Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007 Jul 01; 25(19):2691-5.
Score: 0.003